The Role of Tanshinone IIA in the Treatment of Obesity through Peroxisome Proliferator-Activated Receptor gamma Antagonism

doi:10.1210/en.2008-0322

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 国家新药筛选中心

	The Role of Tanshinone IIA in the Treatment of Obesity through Peroxisome Proliferator-Activated Receptor gamma Antagonism
	Gong, Zhenwei 2; Huang, Cheng 2; Sheng, Xiaoyan 2; Zhang, Yuebo 2; Li, Qunyi 1; Wang, Ming-Wei1 ; Peng, Linling 3,4; Zang, Ying Qin 2
刊名	ENDOCRINOLOGY
	2009-01
卷号	150 期号:1 页码:104-113
ISSN号	0013-7227
DOI	10.1210/en.2008-0322
文献子类	Article
英文摘要	Peroxisome proliferator-activated receptor (PPAR) gamma is a nuclear receptor that coordinates carbohydrate and lipid metabolism, and is a therapeutic target for type 2 diabetes. Tanshinone IIA ( Tan) is a lipophilic diterpene that is widely used to treat cardiovascular diseases in traditional Chinese medicine, and has recently been found to reduce body weight and lower blood lipids. However, its underlying mechanism of antiadipogenic effects remains unknown. Here, we report that Tan inhibits 3T3-L1 preadipocyte differentiation and transcriptional activities of full-length PPAR gamma and PPAR gamma ligand-binding domains. The effects of Tan are mediated through its property as a natural antagonist of PPAR gamma (dissociation constant of an inhibitor value, 2.562 +/- 0.711 mu M). Tan treatment reduced adipose mass and body weight, improved glucose tolerance, and lowered the low-density lipoprotein to high-density lipoprotein ratio without changing the food intake in a high-fat diet-induced obese animal model. Our results suggest that the combined properties of Tan in adipogenesis, glucose tolerance, lipogenesis, and cardiovascular protection are beneficial for treating diabetic patients with complex metabolic conditions, in which modulating a single target is often not sufficient to achieve the desired effect. (Endocrinology 150: 104-113, 2009)
资助项目	Hundred Talent Project of Chinese Academy of Sciences[00000000] ; Ministry of Science and Technology of China[2004CB518902] ; STCSM[07JC14011]
WOS关键词	DIET-INDUCED OBESITY ; PPAR-GAMMA ; SALVIA-MILTIORRHIZA ; IN-VITRO ; ADIPOCYTE DIFFERENTIATION ; INSULIN-RESISTANCE ; HEART-DISEASE ; ADIPOGENESIS ; EXPRESSION ; APOPTOSIS
WOS研究方向	Endocrinology & Metabolism
语种	英语
出版者	ENDOCRINE SOC
WOS记录号	WOS:000262052300013
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/279365]
专题	国家新药筛选中心
通讯作者	Zang, Ying Qin
作者单位	1.Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, Shanghai 201203, Peoples R China; 2.Chinese Acad Sci, Grad Sch, Shanghai Inst Biol Sci, Inst Nutr Sci,Key Lab Nutr & Metab, Shanghai 200031, Peoples R China; 3.Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp Affiliated, Shanghai Inst Hematol, Shanghai 200025, Peoples R China 4.Shanghai Jiao Tong Univ, Sch Med, State Key Lab Med Genom, Shanghai 200025, Peoples R China;
推荐引用方式 GB/T 7714	Gong, Zhenwei,Huang, Cheng,Sheng, Xiaoyan,et al. The Role of Tanshinone IIA in the Treatment of Obesity through Peroxisome Proliferator-Activated Receptor gamma Antagonism[J]. ENDOCRINOLOGY,2009,150(1):104-113.
APA	Gong, Zhenwei.,Huang, Cheng.,Sheng, Xiaoyan.,Zhang, Yuebo.,Li, Qunyi.,...&Zang, Ying Qin.(2009).The Role of Tanshinone IIA in the Treatment of Obesity through Peroxisome Proliferator-Activated Receptor gamma Antagonism.ENDOCRINOLOGY,150(1),104-113.
MLA	Gong, Zhenwei,et al."The Role of Tanshinone IIA in the Treatment of Obesity through Peroxisome Proliferator-Activated Receptor gamma Antagonism".ENDOCRINOLOGY 150.1(2009):104-113.